Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas

Relapsed and refractory high-risk neuroblastoma (NBL) patients have limited treatment options and a poor prognosis, highlighting the urgent need for novel targeted therapies. This study evaluates the GD2-targeting PET imaging agent [<sup>89</sup>Zr]Zr-DFO-hu3F8 and the radioimmunotherapy...

Full description

Saved in:

Bibliographic Details
Main Author:	Lingling Zheng (1628176) (author)
Other Authors:	Xu Yang (112496) (author), Jun Liu (42548) (author), Guanyun Wang (12750872) (author), Zi Ang Zhou (22687999) (author), Yanfeng Xu (2604343) (author), Jianhua Gong (530290) (author), Jigang Yang (5004701) (author)
Published:	2025
Subjects:	Biochemistry Medicine Cell Biology Genetics Molecular Biology Physiology Pharmacology Biotechnology Immunology Cancer Computational Biology Biological Sciences not elsewhere classified targeted therapy based novel targeted therapies limited treatment options igg control group biodistribution analysis showed achieving complete remission 47 ± 3 168 h post confirm targeting efficacy 89 </ sup 225 </ sup positive nbl xenografts nbl animal models using [< sup imr32 tumors compared hu3f8 pet imaging 5 kbq ). [< sup vitro </ therapeutic efficacy urgent need tumor uptake sustained uptake study evaluates single dose risk neuroblastoma poor prognosis neuroblastomas relapsed immunopet revealed findings demonstrate
Tags:	Add Tag No Tags, Be the first to tag this record!

Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas

Similar Items